154 related articles for article (PubMed ID: 36699446)
1. PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers.
Dai J; Cui Y; Liang X; Xu J; Li J; Chen Y; Zhang E; Guo R
Front Genet; 2022; 13():1066347. PubMed ID: 36699446
[No Abstract] [Full Text] [Related]
2. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
[TBL] [Abstract][Full Text] [Related]
4. Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB.
Miao XY; Wu H; Ye BC; Yi QW; Lin FN; Wang YL; Ren CL; Jiang YF; Li A
Sci Rep; 2022 Dec; 12(1):20734. PubMed ID: 36456601
[TBL] [Abstract][Full Text] [Related]
5. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
Hagiwara M; Fushimi A; Matsumoto K; Oya M
Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
[TBL] [Abstract][Full Text] [Related]
6. [Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].
Qin CP; Song YX; Ding MT; Wang F; Lin JX; Yang WB; DU YQ; Li Q; Liu SJ; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):663-668. PubMed ID: 35950389
[TBL] [Abstract][Full Text] [Related]
7.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
[TBL] [Abstract][Full Text] [Related]
9. Association of
Cui Y; Zhang P; Liang X; Xu J; Liu X; Wu Y; Zhang J; Wang W; Zhang F; Guo R
Am J Cancer Res; 2022; 12(4):1766-1783. PubMed ID: 35530271
[TBL] [Abstract][Full Text] [Related]
10. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
Shang X; Zhang W; Zhang X; Yu M; Liu J; Cheng Y; Cheng B
Front Immunol; 2022; 13():991091. PubMed ID: 36248841
[TBL] [Abstract][Full Text] [Related]
11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
12. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
Front Immunol; 2022; 13():834142. PubMed ID: 35242138
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts.
Long JY; Li RZ; Wang DX; Liu H; Tian J; Ding ZN; Yan LJ; Dong ZR; Hong JG; Tian BW; Han CL; Zhao HT; Li T
Int Immunopharmacol; 2024 Jan; 126():111281. PubMed ID: 38061115
[TBL] [Abstract][Full Text] [Related]
14. Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma.
Jee B; Seo E; Park K; Kim YR; Byeon SJ; Lee SM; Chung JH; Song W; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park SH; Park WY; Kang M
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625960
[TBL] [Abstract][Full Text] [Related]
15. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
16.
Zhou H; Liu J; Zhang Y; Huang Y; Shen J; Yang Y; Fang W; Zhang L
NPJ Precis Oncol; 2020; 4():6. PubMed ID: 32195359
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a PBRM1-associated immune prognostic model for clear cell renal cell carcinoma.
Chen J; Yao C; Qiao N; Ge Y; Li J; Lin Y; Yao S
Cancer Med; 2021 Oct; 10(19):6590-6609. PubMed ID: 34535962
[TBL] [Abstract][Full Text] [Related]
18. Significance of PBRM1 mutation in disease progress and drug selection in clear cell renal cell carcinoma.
He D; Ma T; Yi N; Zhang S; Ding G
Biotechnol Genet Eng Rev; 2023 Apr; ():1-15. PubMed ID: 37079762
[TBL] [Abstract][Full Text] [Related]
19. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.
Dong Y; Zhao L; Duan J; Bai H; Chen D; Li S; Yu Y; Xiao M; Zhang Q; Duan Q; Sun T; Qi C; Wang J; Wang Z
Cell Prolif; 2022 Sep; 55(9):e13283. PubMed ID: 35811392
[TBL] [Abstract][Full Text] [Related]
20. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
Boorjian S
Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]